• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by ARYA Sciences Acquisition Corp IV

    2/13/24 8:20:56 PM ET
    $ARYD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ARYD alert in real time by email
    SC 13G 1 d690372dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No.  )*

     

     

    ARYA Sciences Acquisition Corp IV

    (Name of Issuer)

    Common Shares

    (Title of Class of Securities)

    G31659108

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d–1(b)

    ☐ Rule 13d–1(c)

    ☐ Rule 13d–1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. G31659108

     

     (1)   

     Names of reporting persons

     

     Mizuho Financial Group, Inc.

     (2)  

     Check the appropriate box if a member of a group (see instructions)

     (a) ☐  (b) ☒

     

     (3)  

     SEC use only

     

     (4)  

     Citizenship or place of organization

     

     Japan

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

       (5)   

     Sole voting power

     

     332,532**

       (6)  

     Shared voting power

     

     None

       (7)  

     Sole dispositive power

     

     332,532**

       (8)  

     Shared dispositive power

     

     None

     (9)   

     Aggregate amount beneficially owned by each reporting person

     

     332,532**

    (10)  

     Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

     

    (11)  

     Percent of class represented by amount in Row (9)

     

     7.94%

    (12)  

     Type of reporting person (see instructions)

     

     FI

     

    **

    Mizuho Financial Group, Inc., Mizuho Bank, Ltd. and Mizuho Americas LLC may be deemed to be indirect beneficial owners of said equity securities directly held by Mizuho Securities USA LLC which is their wholly-owned subsidiary.

     


      SCHEDULE 13G   Page 3 of 7

     

    Item 1(a) Name of issuer: ARYA Sciences Acquisition Corp IV

    Item 1(b) Address of issuer’s principal executive offices: 51 Astor Place, 10th Floor New York, NY 10003

    2(a) Name of person filing:

    Mizuho Financial Group, Inc.

    2(b) Address or principal business office or, if none, residence:

    1–5–5, Otemachi, Chiyoda–ku, Tokyo 100–8176, Japan

    2(c) Citizenship:

    Japan

    2(d) Title of class of securities:

    Common Shares,

    2(e) CUSIP No.:

    G31659108

     

    Item 3.

    If this statement is filed pursuant to §§240.13d–1(b) or 240.13d–2(b) or (c), check whether the person filing is a:

     

    (a)   ☐

       Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

    (b)   ☐

       Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

    (c)   ☐

       Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

    (d)   ☐

       Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a–8);

    (e)   ☐

       An investment adviser in accordance with §240.13d–1(b)(1)(ii)(E);

    (f)   ☐

       An employee benefit plan or endowment fund in accordance with §240.13d–1(b)(1)(ii)(F);

    (g)   ☐

       A parent holding company or control person in accordance with §240.13d–1(b)(1)(ii)(G);

    (h)   ☐

       A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

    (i) ☐

       A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a–3);

    (j) ☒

       A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);

    (k)   ☐

       Group, in accordance with §240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution: ________________________________

     

    Item 4.

    Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned: 332,532.

    (b) Percent of class: 7.94.


      SCHEDULE 13G   Page 4 of 7

     

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote 332,532.

    (ii) Shared power to vote or to direct the vote None.

    (iii) Sole power to dispose or to direct the disposition of 332,532.

    (iv) Shared power to dispose or to direct the disposition of None.

     

    Item 5.

    Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

    Dissolution of a group requires a response to this item.

     

    Item 6.

    Ownership of More than 5 Percent on Behalf of Another Person.

    Not applicable

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    See Exhibit A

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable

     

    Item 10.

    Certifications

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect other than activities solely in connection with a nomination under §240.14a-11.

    By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to a parent holding company is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution. I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

     


    Signatures

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: 02-13-2024    Signature:   

    /s/ Masaaki Kaneko

       Name:    Masaaki Kaneko
       Title:    Managing Director, Global Corporate Function Coordination Dep.


    Power of Attorney

    Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and the rules and regulations thereunder, the undersigned, in the undersigned capacity as an authorized representative of Mizuho Financial Group, Inc. (the “Company”), hereby grants full power and authority to Masaaki Kaneko, Managing Director, Head of Global Branches & Subsidiaries Coordination Office, Global Corporate Function Coordination Department, to:

     

      1.

    execute on behalf of the undersigned Form 13G in accordance with Section 13(d) and Section 13(g) of the Exchange Act or any rule or regulation thereunder; .

     

      2.

    do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 13G, complete and execute any amendments, restatements, supplements, and/or exhibits thereto, and timely file such form with the U.S. Securities and Exchange Commission (the “SEC”); and

     

      3.

    take any other action in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by or for, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney shall be in such form and shall contain such information and disclosure as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

    The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever required, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney and the rights and powers herein granted.

    The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request and on the behalf of the undersigned, is not assuming any of the undersigned’s responsibilities to comply with, or any liability for the failure to comply with, any provision of Section 13 of the Exchange Act.

    This Limited Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 13G with respect to the Company’s holdings of and transactions in securities, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

    [Signature page to follow]


    SIGNATURE

    IN WITNESS WHEREOF, the undersigned hereby has caused this Power of Attorney to be executed.

    Mizuho Financial Group, Inc.

     

    Date: 02-13-2024    Signature:   

    /s/ Hidekatsu Take

       Name:    Hidekatsu Take
       Title:    Senior Executive Officer

     

    Get the next $ARYD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARYD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ARYD
    Financials

    Live finance-specific insights

    See more
    • Amicus Therapeutics and ARYA Sciences Acquisition Corp IV Announce Formation of a Next-Generation Genetic Medicine Company: "Caritas Therapeutics"

      Business Combination of Amicus Gene Therapy Business with ARYA IV to Result in the Launch of Caritas Therapeutics, a New Independent, Publicly Traded Company with Expected ~$400M in Initial Funding Will Transform Amicus into a Premier Global Commercialization and Late Stage Product Development Biotechnology Company in Rare Diseases Transaction Advances Amicus Path to Profitability - Expected as of 2023 Amicus Balance Sheet Further Strengthened with a ~$200M Private Investment from Leading Biotechnology Investors Separation will Sharpen the Strategic Focus, Financial Profile, and Operational Execution of Both Companies to Address the Needs of People Living with Rare Diseases – A

      9/29/21 6:30:00 AM ET
      $ARYD
      $FOLD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $ARYD
    SEC Filings

    See more
    • SEC Form 15-12G filed by ARYA Sciences Acquisition Corp IV

      15-12G - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)

      8/12/24 4:30:11 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 25-NSE filed by ARYA Sciences Acquisition Corp IV

      25-NSE - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)

      7/31/24 5:16:44 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ARYA Sciences Acquisition Corp IV filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)

      7/26/24 4:30:22 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARYD
    Leadership Updates

    Live Leadership Updates

    See more
    • Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

      MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders' Meeting, the Company's shareholders approved the appointment of five directors to the Company's Board of Directors, effective as of May 2, 2024, including four new members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and

      5/6/24 6:25:00 AM ET
      $ARYD
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARYD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Stone Adam Leo returned 499,000 units of Class A ordinary shares to the company (SEC Form 4)

      4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)

      7/31/24 9:52:23 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Henderson Michael Thomas

      4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)

      7/31/24 9:49:31 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Trigg Leslie

      4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)

      7/31/24 9:46:16 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARYD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ARYA Sciences Acquisition Corp IV

      SC 13G/A - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)

      6/28/24 5:09:55 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by ARYA Sciences Acquisition Corp IV (Amendment)

      SC 13G/A - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)

      5/10/24 4:31:19 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by ARYA Sciences Acquisition Corp IV

      SC 13G - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)

      2/14/24 3:30:36 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARYD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Adagio Medical Provides Business Updates

      Adagio Medical Holdings, Inc. (NASDAQ:ADGM, the "Company"))), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today provided a business update. Recent Business Highlights: Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal Obtained the U.S. Food and Drug Administration ("FDA") approval for the FULCRUM-VT Pivotal IDE study Cl

      8/19/24 4:01:00 PM ET
      $ADGM
      $ARYD
      Medical/Dental Instruments
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Adagio Medical Announces the Closing of the Business Combination with ARYA IV, Creating a Publicly Traded Company Focused on the Innovative Technologies for Treatment of Cardiac Arrhythmias

      Business combination transaction with ARYA Sciences Acquisition Corp IV, a special purpose acquisition company sponsored by an affiliate of Perceptive Advisors, closed on July 31, 2024 Publicly traded company renamed Adagio Medical Holdings, Inc., with Adagio Medical as an operating subsidiary Common stock expected to commence trading under ticker symbol "ADGM" on the Nasdaq Capital Market on August 1, 2024 Adagio Medical, Inc. ("Adagio Medical"), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, announced today the completion of its business combination with ARYA Sciences Acquisition Corp IV (NASDAQ:ARYD, or "ARYA IV"))), a special purpos

      7/31/24 4:01:00 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

      MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders' Meeting, the Company's shareholders approved the appointment of five directors to the Company's Board of Directors, effective as of May 2, 2024, including four new members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and

      5/6/24 6:25:00 AM ET
      $ARYD
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care